Perjeta 420mg Injection (Pertuzumab) – Complete Product Description

Perjeta 420mg Injection (Pertuzumab) is a prescription oncology medicine manufactured by Roche. It contains pertuzumab, a recombinant humanized monoclonal antibody used as a targeted cancer therapy for selected patients with HER2-positive breast cancer.

Perjeta works by specifically targeting the HER2 (human epidermal growth factor receptor 2) protein on cancer cells. It binds to a different region of the HER2 receptor than trastuzumab and interferes with HER2-related signaling pathways that can promote cancer-cell growth and survival. Pertuzumab is commonly used as part of a combination treatment regimen with trastuzumab and chemotherapy when clinically appropriate.

The Perjeta 420mg Injection presentation contains 420mg of pertuzumab in 14mL and is supplied as a concentrate for solution for intravenous infusion. The product listed here is manufactured by Roche and supplied in a pack size of 1 injection/vial.

Perjeta 420mg Injection – Product Information

Brand Name: Perjeta
Active Ingredient: Pertuzumab
Strength: 420mg
Presentation: 420mg/14mL
Dosage Form: Concentrate for solution for infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Roche
Pack Size: 1 injection
Drug Class: HER2-targeted monoclonal antibody
Therapeutic Class: Antineoplastic / Targeted cancer therapy
Prescription Status: Prescription medicine

Perjeta is a specialized biological medicine and must be prepared and administered by an appropriately trained healthcare professional.

What Is Perjeta 420mg Injection Used For?

Perjeta (Pertuzumab) is primarily used as part of specific treatment regimens for HER2-positive breast cancer.

Depending on the approved indication and treatment setting, pertuzumab may be used for:

• HER2-positive early breast cancer
• HER2-positive locally advanced breast cancer
• HER2-positive inflammatory breast cancer
• HER2-positive metastatic breast cancer

Perjeta is generally used in combination with trastuzumab and chemotherapy in appropriate patients. The exact treatment combination depends on the patient’s diagnosis, stage of cancer, HER2 status, previous treatment and overall health.

Perjeta for HER2-Positive Breast Cancer

Some breast cancers produce abnormally high levels of HER2 protein. These are known as HER2-positive breast cancers.

HER2 can contribute to cancer-cell growth and proliferation. Perjeta targets HER2 and prevents certain HER2 signaling interactions. When used together with trastuzumab, pertuzumab can provide complementary HER2 blockade because the two antibodies bind to different regions of the HER2 receptor.

Perjeta for Early Breast Cancer

Perjeta may be incorporated into treatment for selected patients with HER2-positive early breast cancer, including patients with higher-risk disease.

Depending on the clinical situation, pertuzumab may be given before surgery as part of neoadjuvant therapy and/or after surgery as part of an appropriate treatment plan.

Perjeta for Locally Advanced or Inflammatory Breast Cancer

For selected patients with HER2-positive locally advanced or inflammatory breast cancer, Perjeta may be included in a combination treatment regimen before surgery.

The treating oncologist determines whether this approach is appropriate based on the patient’s tumor characteristics and clinical condition.

Perjeta for Metastatic Breast Cancer

Perjeta is also used for selected patients with HER2-positive metastatic breast cancer.

In this setting, pertuzumab is commonly administered in combination with trastuzumab and a taxane-based chemotherapy regimen when appropriate.

The treatment plan is individualized according to previous therapy, disease progression and the patient’s overall condition.

How Does Perjeta (Pertuzumab) Work?

Perjeta contains pertuzumab, a HER2-targeted monoclonal antibody.

HER2 is a receptor located on the surface of certain cells. In HER2-positive cancer, increased HER2 signaling can promote tumor-cell growth and survival.

Pertuzumab binds to the dimerization domain of HER2, interfering with HER2’s ability to pair with other HER-family receptors. This can reduce signaling pathways involved in cancer-cell proliferation.

Pertuzumab can also stimulate immune-mediated destruction of HER2-expressing cancer cells.

Perjeta and Herceptin: Complementary HER2 Targeting

Perjeta is often used together with trastuzumab (Herceptin) because the two medicines target different regions of the HER2 receptor.

This complementary mechanism provides a more comprehensive blockade of HER2 signaling in appropriate patients.

Perjeta itself is not traditional chemotherapy. It is a targeted biological therapy that may be administered together with chemotherapy.

HER2 Testing Before Perjeta Treatment

Perjeta is intended for patients whose tumors have appropriate HER2-positive status.

Before treatment, healthcare professionals may evaluate HER2 status using validated diagnostic tests such as:

• Immunohistochemistry (IHC)
• In situ hybridization (ISH)
• Other approved HER2 testing methods

The treating oncologist will review the pathology results and other clinical factors to determine whether Perjeta is appropriate.

Perjeta 420mg Dose and Administration

Perjeta 420mg is administered through intravenous infusion after appropriate preparation and dilution.

The commonly used maintenance dose is 420mg every 3 weeks, following an appropriate loading dose when initiating treatment. The exact regimen depends on the patient’s treatment setting and the prescribing physician’s instructions.

Perjeta may be administered together with trastuzumab and chemotherapy as part of an approved treatment protocol.

The infusion should be administered by a qualified healthcare professional in an appropriate medical setting.

Do not self-inject Perjeta 420mg.

The first infusion may require longer monitoring, particularly because infusion-related and hypersensitivity reactions can occur.

Common Side Effects of Perjeta 420mg

Like all medicines, Perjeta can cause side effects. The frequency and severity vary among patients, particularly depending on whether it is administered with chemotherapy and other HER2-targeted treatments.

Commonly reported adverse effects may include:

• Diarrhea
• Hair loss
• Nausea
• Fatigue
• Rash
• Decreased appetite
• Vomiting
• Headache
• Muscle pain
• Joint pain
• Weakness
• Infusion-related reactions
• Low blood cell counts when used with chemotherapy

Patients should discuss persistent or bothersome side effects with their healthcare provider.

Serious Side Effects of Perjeta

Although many patients receive Perjeta without severe complications, serious adverse reactions can occur.

Heart Problems

Perjeta may cause left ventricular dysfunction and decreased heart function, particularly when used with other HER2-directed treatments.

Your doctor may evaluate heart function before treatment and periodically during therapy.

Report symptoms such as:

• Shortness of breath
• Swelling of the ankles or legs
• Unusual fatigue
• Persistent cough
• Rapid or irregular heartbeat
• Sudden weight gain

Infusion-Related Reactions

Perjeta can cause infusion-related reactions during or shortly after administration.

Symptoms may include:

• Fever
• Chills
• Headache
• Dizziness
• Nausea
• Difficulty breathing
• Changes in blood pressure
• Weakness

Healthcare professionals monitor patients during and after infusion and manage reactions according to their severity.

Hypersensitivity and Anaphylaxis

Serious hypersensitivity reactions, including anaphylaxis, can occur rarely.

Patients should be monitored during administration and should immediately report breathing difficulty, facial swelling, severe dizziness or other signs of a severe allergic reaction.

Diarrhea

Diarrhea is a commonly reported adverse effect of pertuzumab. Severe or persistent diarrhea can result in dehydration and may require medical treatment.

Precautions Before Using Perjeta 420mg

Before receiving Perjeta, inform your doctor if you have:

• A history of heart disease
• Heart failure
• High blood pressure
• Reduced heart function
• Previous treatment with certain chemotherapy medicines
• Previous severe reactions to monoclonal antibodies
• Any known allergy to pertuzumab or related medicines

Tell your healthcare provider about all prescription medicines, over-the-counter medicines, supplements and other cancer treatments you are receiving.

Perjeta and Heart Monitoring

Because HER2-targeted medicines can affect cardiac function, heart health is an important consideration during treatment.

Your healthcare provider may perform an echocardiogram or another cardiac assessment before starting treatment and at intervals during therapy.

Patients with significant pre-existing cardiac conditions may require additional evaluation before treatment.

Perjeta During Pregnancy

Perjeta can cause fetal harm when administered during pregnancy because HER2 signaling plays an important role in fetal development.

Women who can become pregnant should discuss effective contraception with their healthcare provider before starting treatment and during the recommended period following treatment.

If pregnancy occurs while receiving Perjeta, notify the treating healthcare professional immediately.

Perjeta and Breastfeeding

Patients should discuss breastfeeding with their doctor before starting Perjeta.

Because pertuzumab is a specialized biological medicine and may pose potential risks to a breastfed infant, the healthcare provider will advise whether breastfeeding should be discontinued during treatment and for the appropriate period afterward.

Perjeta 420mg Storage

Perjeta is a temperature-sensitive biological medicine and must be stored according to the manufacturer’s approved storage requirements.

The unopened vial should generally be stored under refrigerated conditions and protected from light.

Do not freeze or shake Perjeta.

The medicine should be prepared and handled by qualified healthcare professionals or authorized pharmaceutical personnel.

Perjeta 420mg Injection Price in Pakistan

The Perjeta 420mg Injection price in Pakistan may vary depending on supplier, availability, import costs, exchange rates and prevailing market conditions.

For the latest Perjeta 420mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

Because specialized oncology medicines can have changing prices, customers should confirm the latest price before placing an order.

Why Choose Perjeta 420mg Injection?

Perjeta contains pertuzumab, an established HER2-targeted monoclonal antibody used as part of combination treatment for selected patients with HER2-positive breast cancer.

Its complementary mechanism with trastuzumab allows oncologists to target HER2 signaling at different sites of the receptor.

The Roche-manufactured Perjeta 420mg/14mL presentation provides a maintenance-dose vial intended for intravenous infusion under professional medical supervision.

Frequently Asked Questions About Perjeta 420mg

What is Perjeta 420mg Injection?

Perjeta 420mg Injection is a prescription targeted cancer medicine containing pertuzumab, a monoclonal antibody that targets the HER2 receptor.

What is the generic name of Perjeta?

The generic name is pertuzumab.

Who manufactures Perjeta 420mg Injection?

The manufacturer of the product listed here is Roche.

What is the pack size of Perjeta 420mg?

The pack size for this product is 1 injection/vial.

How is Perjeta 420mg administered?

Perjeta 420mg is administered by intravenous infusion after appropriate dilution and preparation by a qualified healthcare professional.

How often is Perjeta 420mg given?

After the appropriate loading dose, the commonly used maintenance dose is 420mg every 3 weeks, according to the prescribed treatment regimen.

Is Perjeta chemotherapy?

No. Perjeta is a targeted biological therapy and monoclonal antibody. It may be used together with chemotherapy and trastuzumab as part of certain cancer treatment regimens.

What is Perjeta used for?

Perjeta is primarily used in selected patients with HER2-positive breast cancer, including certain early, locally advanced and metastatic disease settings.

Is Perjeta used with Herceptin?

Yes. Pertuzumab is commonly used together with trastuzumab because the two antibodies bind to different regions of the HER2 receptor and provide complementary HER2 targeting.

Does Perjeta require HER2 testing?

Yes. Appropriate HER2 testing is important before initiating HER2-targeted treatment.

Can Perjeta be purchased without a prescription?

Perjeta is a specialized prescription oncology medicine and should only be used under the supervision of a qualified oncologist or healthcare professional.

Order Perjeta 420mg Injection in Pakistan

Looking for Perjeta 420mg Injection (Pertuzumab) by Roche in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and oncology products. Contact us to check the latest Perjeta 420mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Perjeta 420mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Perjeta 420mg Injection is a prescription cancer medicine. This product description is intended for educational and e-commerce purposes only and does not replace professional medical advice. Perjeta should be prescribed, prepared and administered by qualified healthcare professionals. Do not change the dose, treatment schedule or duration without medical advice.